Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2-Negative Breast Cancer: The I-SPY2 Randomized Clinical Trial.
Journal: JAMA oncology
Published: July 30, 2026
Neoadjuvant Palbociclib Treatment Impacts Cell Cycle Progression of DCIS.
Journal: Cancers
Published: July 18, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 10, 2026
Serum analytes as predictors of disease recurrence and the duration of invasive disease-free survival in patients with triple negative breast cancer enrolled in the OXEL trial treated with immunotherapy, chemotherapy, or chemoimmunotherapy.
Journal: Journal for immunotherapy of cancer
Published: April 07, 2025
Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: Nature communications
Published: May 10, 2024
The Aspirin Conundrum-Navigating Negative Results, Age, Aging Dynamics, and Equity.
Journal: JAMA
Published: April 29, 2024
Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
Journal: Journal of the American Medical Informatics Association : JAMIA
Published: April 03, 2024
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: medRxiv : the preprint server for health sciences
Published: December 18, 2023
Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study.
Journal: Nature communications
Published: January 05, 2023
A phase I trial of palbociclib and bosutinib with fulvestrant in patients with metastatic hormone receptor positive and HER2 negative (HR+ HER2-) breast cancer refractory to an aromatase inhibitor and a CDK4/6 inhibitor.
Journal: Contemporary clinical trials communications
Published: September 29, 2022
Last Updated: 09/26/2026